Apollomics has articulated a clear vision for the utilization of the net proceeds from this financing round. Apollomics Inc. (Nasdaq: APLM), a burgeoning force in the clinical-stage biopharmaceutical arena, has recently announced a strategic private investment in public equity (PIPE) financing. This bold step is poised to inject approximately $6 million in gross proceeds into the company, prior to the ded...
$アポロミクス A(APLM.US)$Apollomics Completed Patient Enrollment For The Uproleselan (Apl-106) Phase 3 Bridging Study In China – Topline Data Expected In The First Half Of 2025
$アポロミクス A(APLM.US)$Apollomics Completes Enrollment In Phase 3 Bridging Study Of Uproleselan (APL-106) Added To A Standard Chemotherapy Regimen In Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia Benzinga· 3 mins ago
$アポロミクス A(APLM.US)$still have a bag on this. ill a erage down and aim to get out. misplayed this. poor entry and didnt exit at gains. win some lose some.
Unknown Variable :
it's dipping because the volume is low at the moment. hopefully it will get an uptick after the holidays are over and people resume their usual trading activities again.
アポロミクス Aに関するコメント
Apollomics Inc. (Nasdaq: APLM), a burgeoning force in the clinical-stage biopharmaceutical arena, has recently announced a strategic private investment in public equity (PIPE) financing. This bold step is poised to inject approximately $6 million in gross proceeds into the company, prior to the ded...
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Benzinga· 3 mins ago
まだコメントはありません